2023 Annual Performance Forecast
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
2023 Annual Performance Forecast
Filed with SSE ·
2023 Annual Performance Forecast
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
6ix hasn’t read this filing yet.
Shanghai Allist Pharmaceuticals Co. Ltd. on 6ix
Earlier from Shanghai Allist Pharmaceuticals
- Announcement on Voluntary Disclosure of Publicity of Furmonertinib Mesilate Tablets for First-line Indication Treatment of EGFR20 Exon Insertion Mutated NSCLC Included in Potential Breakthrough Therapy Variety
- Announcement on Resolution of 6th Session of 2nd Board of Supervisors
Later from Shanghai Allist Pharmaceuticals
- Announcement on 2023 Annual Preliminary Earnings Estimate
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of AST2169 Liposome for Injection
- Special Report on Storage and Actual Use of Raised Funds in 2023
- Announcement on Resolutions of 2023 Annual General Meeting
- Announcement on Implementation of Dividend Distribution for 2023
Follow Shanghai Allist Pharmaceuticals into a list and get an email when it puts out news.
Follow Shanghai Allist Pharmaceuticals